<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04988542</url>
  </required_header>
  <id_info>
    <org_study_id>TD-SQ-001</org_study_id>
    <nct_id>NCT04988542</nct_id>
  </id_info>
  <brief_title>Clinical Efficacy of a Supplement on Sleep Quality</brief_title>
  <official_title>Clinical Efficacy of a Novel Delivery Supplement on Sleep Quality</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TruDiagnostic</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Circadian Wellness Corp</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>TruDiagnostic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective randomized clinical study of 30 patients to evaluate a novel sleep&#xD;
      supplement. This study will be evaluating the effectiveness of the supplement over a 2 month&#xD;
      program. The study will assess the effects that the supplement has on a patient's sleep&#xD;
      metrics and epigenetic age biomarkers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 30, 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Patients will be in the control group for 1 month and in the intervention group for one month</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Epigenetic Age</measure>
    <time_frame>Change from baseline to 2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sleep duration</measure>
    <time_frame>change from baseline to 2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Sleep</condition>
  <arm_group>
    <arm_group_label>Sleep supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Circadian Wellness sleep SL strip nightly for 30 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in the control group will have no intervention and no change in their usual daily routine or supplements. They will be asked to not take any sleep aid supplement during the study period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Circadian Wellness sleep SL strip</intervention_name>
    <description>Participants in the intervention group will be asked to begin Circadian Wellness sleep SL strip nightly for 30 days. Participants will continue the supplementation for the 30 days.</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Sleep supplement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women of any ethnicity.&#xD;
&#xD;
          -  Age Range - 16 - 65&#xD;
&#xD;
          -  Patient must be able to comply with treatment plan and laboratory tests&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Neoplastic cancer within 5 years prior to screening, except for cutaneous basal cell&#xD;
             or squamous cell cancer resolved by excision&#xD;
&#xD;
          -  No immune system issues or immunodeficiency disease&#xD;
&#xD;
          -  No history of viral illness which could be reactivated by immune downregulation&#xD;
&#xD;
          -  Presence of clinically significant acute or unstable cardiovascular and&#xD;
             cerebrovascular (stroke)&#xD;
&#xD;
          -  Diagnosis of a transient ischemic attack in the 6 months prior to screening&#xD;
&#xD;
          -  Patients infected with hepatitis, C or HIV&#xD;
&#xD;
          -  Patients with Body Mass Index (BMI) &gt; 40 kg/m2&#xD;
&#xD;
          -  Presence of active infection&#xD;
&#xD;
          -  Any other illness, psychiatric disorder, alcohol or chemical dependence that in the&#xD;
             opinion of the investigator would render a patient unsuitable to participate in the&#xD;
             study&#xD;
&#xD;
          -  Unable or unwilling to provide required blood sample for testing&#xD;
&#xD;
          -  As for the male-participants they are recommended to avoid fertilization for the first&#xD;
             6 months after the clinical trial.&#xD;
&#xD;
          -  If the patient has previously used any products in a month prior to the start of the&#xD;
             trial.&#xD;
&#xD;
          -  Known sleep disorder ie. obstructive sleep apnea&#xD;
&#xD;
          -  Presence of schizophrenia, bipolar disorder&#xD;
&#xD;
          -  Concurrent use of cannabis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjeev Goel</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peak Human Labs</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sanjeev Goel, MD</last_name>
    <phone>647-966-4385</phone>
    <email>DRGOEL@PEAKHUMAN.CA</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annie Prestrud</last_name>
    <email>annie@trudiagnostic.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Cui XY, Cui SY, Zhang J, Wang ZJ, Yu B, Sheng ZF, Zhang XQ, Zhang YH. Extract of Ganoderma lucidum prolongs sleep time in rats. J Ethnopharmacol. 2012 Feb 15;139(3):796-800. doi: 10.1016/j.jep.2011.12.020. Epub 2011 Dec 21.</citation>
    <PMID>22207209</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 26, 2021</study_first_submitted>
  <study_first_submitted_qc>July 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2021</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

